Skip to Content

Join the 'Ranibizumab' group to help and get support from people like you.

Ranibizumab News

FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy

Posted 28 Mar 2018 by Drugs.com

South San Francisco, CA – March 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. In April 2017, Lucentis 0.3 mg became, and remains, ...

FDA Approves Genentech’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy

Posted 19 Apr 2017 by Drugs.com

South San Francisco, CA – April 17, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of ...

FDA Approves Genentech’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization

Posted 10 Feb 2017 by Drugs.com

South San Francisco, CA – January 5, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness. Lucentis is the ...

FDA Approves Genentech’s Lucentis (ranibizumab) Prefilled Syringe

Posted 17 Oct 2016 by Drugs.com

South San Francisco, CA – October 14, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related ...

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found ...

Drug Lucentis May Fight Diabetic Eye Disease

Posted 13 Nov 2015 by Drugs.com

FRIDAY, Nov. 13, 2015 – The injected drug Lucentis (ranibizumab) appears highly effective at treating proliferative diabetic retinopathy, a common diabetes-related eye disease, new research shows. Investigators say the drug beat a standard treatment, laser therapy, in curbing the vision-robbing ailment. The findings, "provide crucial evidence for a safe and effective alternative to laser therapy ...

Drug Avastin Not Linked to Higher Risk of Blindness: Study

Posted 13 Aug 2015 by Drugs.com

THURSDAY, Aug. 13, 2015 – Concerns that eye injections of the drug Avastin increase the risk of a potentially blinding eye infection may be unfounded, a new study finds. Researchers analyzed insurance claims data from across the United States to compare the use of Avastin (bevacizumab) to treat retinal diseases with a much more expensive drug called Lucentis (ranibizumab). The study was ...

Lucentis Approved for Diabetic Retinopathy

Posted 9 Feb 2015 by Drugs.com

MONDAY, Feb. 9, 2015 – A drug to treat the most common eye disease among diabetics has been approved by the U.S. Food and Drug Administration. Lucentis (ranibizumab) has been sanctioned to treat diabetic retinopathy, the leading cause of blindness among adults in the United States, the FDA said in a news release. In 2008, one-third of diabetic adults 40 or older had some form of diabetic ...

FDA Approves Lucentis as First Drug for Diabetic Retinopathy

Posted 8 Feb 2015 by Drugs.com

FRIDAY, Feb. 6, 2015 – The U.S. Food and Drug Administration on Friday approved the drug Lucentis (ranibizumab) to treat diabetic retinopathy in patients with diabetic macular edema. A leading cause of blindness among adults in the United States, diabetic retinopathy is the most common diabetic eye disease, the agency said in a news release. In 2008, 33 percent of adults with diabetes aged 40 or ...

FDA Approves Lucentis (ranibizumab) to Treat Diabetic Retinopathy in People with Diabetic Macular Edema

Posted 6 Feb 2015 by Drugs.com

February 6, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). Diabetic retinopathy is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and ...

FDA Approves Lucentis (ranibizumab) for Treatment of Diabetic Macular Edema (DME)

Posted 13 Aug 2012 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 10, 2012 - Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness. Diabetes is now the ...

Newer Therapies for Eye Disorder Not Tied to Heart Problems

Posted 12 Oct 2010 by Drugs.com

TUESDAY, Oct. 12 – Use of the drugs bevacizumab (Avastin) and ranibizumab (Lucentis) to treat age-related macular degeneration (AMD) doesn't appear to increase the risk of cardiovascular problems or death, a new study suggests. AMD is the most common cause of irreversible vision loss among older Americans. About 12 percent of cases are neovascular ("wet") AMD, which occurs when new blood vessels ...

FDA Approves Lucentis (ranibizumab) for the Treatment of Macular Edema Following Retinal Vein Occlusion

Posted 23 Jun 2010 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 23, 2010 - Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review. "This approval provides an ...

Drug a New Treatment Option for Diabetic Eye Disease

Posted 29 Apr 2010 by Drugs.com

WEDNESDAY, April 28 – A new drug may be the first new treatment in 25 years for a common diabetes-linked eye condition called diabetic macular edema (DME), researchers report. Lucentis (ranibizumab) was originally developed to treat age-related macular degeneration. But researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy. The study of 691 patients ...

Drug-Laser Combination Proves Effective For Diabetic Blindness

Posted 28 Apr 2010 by Drugs.com

Drug-Laser Combination Proves Effective For Diabetic blindness [Los Angeles Times] From Los Angeles Times (CA) (April 28, 2010) Apr. 28--For the first time in a quarter of a century, researchers have identified a new treatment for diabetic macular edema, a potentially blinding disorder that affects about 1 million Americans, researchers said Tuesday. The treatment uses a drug called ranibizumab, ...

Ask a Question

Further Information

Related Condition Support Groups

Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema, Myopic Choroidal Neovascularization

Related Drug Support Groups

Lucentis

Ranibizumab Patient Information at Drugs.com